Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-151

First 151 Last

Share
Profile

Follow
tommttapshoes

163 Posts.

195

28/05/24

12:52

Post #: 74043591
Share

Originally posted by baldwidx: ↑

Eagle - I wonder if you or some other posters might have more insight into the following.

Do you know if you can go straight to a P3 trial for an indication, in a drug that has been proven to be safe and effective? For example, if we get PMS and PHS through registration and into sales, presumably the FDA has deemed the drug to be not just effective v placebo, but safe.

JP referenced this yesterday when he mentioned not needing to undertake P2 trials given they are mainly used to determine dosing and safety. If we take appropriate dosing as a given, following his comments and if we take safety as a given, especially if we took one or both conditions through registration, then is it possible that we have a "straight to P3" pass?

If that is possible, then I think that SIGNIFICANTLY changes the landscape for Neuren - I can't see a TO being accepted unless its absolutely astronomical - numbers we don't even dare to discuss. Why would you not run through P3 after P3 yourself and keep all the profit??

if you have sufficient funds in the short term to run the PMS and PHS trials through to marketing, you may need a small CR (pending updated Daybue Revenue) to keep the lights running but you would quickly bring in so much money from those two that can be reinvested into AMS and then PWS and so on.

It really does shift the paradigm but I guess its all predicated on whether a "straight to P3" scenario is possible.

Has anyone come across it before in a similar platform drug?

Expand

Interesting question" As far as I am aware (I am clinical not research), the answer is yes. Many examples in oncology, and the whole idea of re-purposing drugs, in essence, utilises this pathway. Might well be something neuren are thinking of!

NEU Price at posting: $23.36 Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Almonty Industries – Now it is getting critical!

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

MEM

Many are concerned about global falling birthrates. This diverse stock has solutions

LU7

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

First 151 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $13.27		Change 0.420(3.27%)		Mkt cap ! $1.652B

Open	High	Low	Value	Volume
$13.15	$13.37	$12.92	$4.232M	322.6K

Buyers (Bids)

No.	Vol.	Price($)
2	76	$13.27

Sellers (Offers)

Price($)	Vol.	No.
$13.28	392	5

View Market Depth

No.	Vol.	Price($)
11	313	13.230
6	550	13.220
16	3126	13.210
8	1680	13.200
4	1270	13.190

Price($)	Vol.	No.
13.250	115	5
13.260	867	11
13.270	1648	10
13.280	1495	8
13.290	2261	6

Last trade - 12.12pm 18/06/2025 (20 minute delay)

NEU (ASX) Chart

Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-151

Almonty Industries – Now it is getting critical!

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-151

Top Stories

Almonty Industries – Now it is getting critical!

ASX Market Open: Shares down as Trump threatens 'real end' to Israel-Iran conflict | June 18

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Many are concerned about global falling birthrates. This diverse stock has solutions

Lithium Universe leaps 40% after buying rights to flashy solar panel recycling tech

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News